Pfizer, Biocon Brush Off Deal Talks As Speculative, But Is There Fire Behind The Smoke?
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Possibilities of a collaborative deal between Pfizer and Biocon have been dismissed as highly speculative by both companies for the last few weeks but going by the latest indications, the two could well be on course to joining forces for a few "significant projects.
You may also be interested in...
Is The Pfizer-Biocon Insulin Deal In Trouble? Some Say It May Be Off
A source indicates the deal may soon see its end, which would be a setback for both companies in expanding their diabetes businesses.
PhamAsia News Top Editors' Picks Of 2010
More outsourcing of clinical trials and manufacturing to Asia continued in 2010 as both U.S. and European pharma companies allocated more resources to emerging markets where growth is expected to remain in the double digits for the next five years. At the same time, more M&As and consolidation occurred in a frantic search for innovation that will likely continue. As patents begin to expire, readers can expect many Asian companies to grab the spotlight with biosimilar strategies increasingly coming out of Asia
PhamAsia News Top Editors' Picks Of 2010
More outsourcing of clinical trials and manufacturing to Asia continued in 2010 as both U.S. and European pharma companies allocated more resources to emerging markets where growth is expected to remain in the double digits for the next five years. At the same time, more M&As and consolidation occurred in a frantic search for innovation that will likely continue. As patents begin to expire, readers can expect many Asian companies to grab the spotlight with biosimilar strategies increasingly coming out of Asia